TSX Penny Stocks To Watch In May 2025

In This Article:

With Canada's election now behind it, one source of uncertainty has been removed, allowing policymakers to focus on trade and economic issues. As the market adjusts to these changes, investors are keenly watching for opportunities that align with evolving fiscal policies and potential interest rate cuts. Penny stocks, though a somewhat outdated term, still represent smaller or newer companies that can offer value when backed by strong financials. We've identified three such stocks that may provide both stability and growth potential in today's shifting landscape.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Westbridge Renewable Energy (TSXV:WEB)

CA$0.80

CA$79.91M

★★★★★★

NTG Clarity Networks (TSXV:NCI)

CA$2.19

CA$89.28M

★★★★★★

Thor Explorations (TSXV:THX)

CA$0.64

CA$432.44M

★★★★☆☆

Orezone Gold (TSX:ORE)

CA$1.14

CA$623.15M

★★★★★☆

McChip Resources (TSXV:MCS)

CA$0.78

CA$3.94M

★★★★☆☆

PetroTal (TSX:TAL)

CA$0.56

CA$512.64M

★★★★★☆

Pulse Seismic (TSX:PSD)

CA$2.55

CA$128M

★★★★★★

McCoy Global (TSX:MCB)

CA$3.23

CA$88.57M

★★★★★★

Findev (TSXV:FDI)

CA$0.47

CA$13.32M

★★★★★★

Enterprise Group (TSX:E)

CA$1.64

CA$124.83M

★★★★★☆

Click here to see the full list of 917 stocks from our TSX Penny Stocks screener.

Let's dive into some prime choices out of the screener.

InnoCan Pharma

Simply Wall St Financial Health Rating: ★★★★★★

Overview: InnoCan Pharma Corporation is a pharmaceutical technology company that develops drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients, operating in the United States, Canada, Europe, and internationally, with a market cap of CA$52.64 million.

Operations: The company generates revenue primarily from online sales, amounting to $29.40 million.

Market Cap: CA$52.64M

InnoCan Pharma, with a market cap of CA$52.64 million, remains pre-revenue but has shown significant progress in reducing losses by 15.1% annually over the past five years. The company is debt-free and maintains a stable cash runway exceeding three years based on current free cash flow, providing financial resilience despite an unqualified auditor's opinion expressing going concern doubts. Recent strategic moves include securing patent allowances for its CBD-based technologies in Mexico and filing applications in China, enhancing its intellectual property portfolio across key markets. These developments support InnoCan's efforts to penetrate new regions and strengthen its position in cannabidiol-based therapeutic solutions.